All In MedTech

FDA Clearance Tracker · P050052-S091

RADIESSE INJECTABLE IMPLANT (DERMAL FILLERS)

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Apr 26, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Apr 26, 2017

Approved

Time to decision

98 days

Received Jan 18, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P050052-S091
Device name
RADIESSE INJECTABLE IMPLANT (DERMAL FILLERS)
Applicant location
Franksville, WI
Received
Jan 18, 2017
Decided
Apr 26, 2017
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol - OSB
Original approval
P050052

Device type

Device class
Class III

Every decision under product code LMH

FDA's approval statement

As written in FDA's record.

Approval for changes to the protocol for the post-approval study (PAS) protocol.

Source documents

Other decisions for Merz North America, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

6 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.